Vimarsana
Biggest News Aggregation in the World

Page 6 - Pocare Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pocare Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pocare Network Today - Breaking & Trending Today

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair - Vimarsana News

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repairInvestigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (“SVF”) injections after rotator cuff surger...

Orgenesis Inc reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy - Vimarsana News

Orgenesis Inc reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy

Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy Revenue in the three months came in at $9.4 million, up from $1.8 million in the first quarter of 2020 It identifies promising new therapies and leverages its POCare Platform to provide a pathway for them to reach and treat large numbers of patients at lowered costs Orgenesis Inc (NASDAQ:ORGS) (FRA:45O), the cell and gene therapies (CGTs) focused biotech, reported a four-fold increase in revenue in its first quarter to end-March, as the company continues its journey to build a long-te...

Orgenesis enters second phase of collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with exclusive license to commercialize Celyv - Vimarsana News

Orgenesis enters second phase of collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with exclusive license to commercialize Celyv

Orgenesis enters second phase of collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with exclusive license to commercialize Celyvir solid tumor therapy The collaboration is focused on advancing clinical development and commercialization of the oncolytic virus-based cell therap...

Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy - Vimarsana News

Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy

Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy The collaboration is focused on advancing clinical development and commercialization of the oncolytic virus-based cell therapy March 11, 2021 07:00 ET | Source: Orgenesis Inc. Orgenesis Inc. GERMANTOWN, Md., March 11, 2021 (GLOBE NEWSWIRE) -- . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene ther...

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collab - Vimarsana News

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collab

Search jobs 10-Mar-2021 Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea   . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotec...